---
title: "Morgan Stanley: Raises MicroPort Medbot-B target price to HKD 30.9 and upgrades rating to \"Overweight\""
description: "JP Morgan released a research report stating that MicroPort Medbot-B's order trend in the first half of the year was stronger than expected, indicating a structural shift in the company's growth and p"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/255719520.md"
published_at: "2025-09-03T05:52:04.000Z"
---

# Morgan Stanley: Raises MicroPort Medbot-B target price to HKD 30.9 and upgrades rating to "Overweight"

> JP Morgan released a research report stating that MicroPort Medbot-B's order trend in the first half of the year was stronger than expected, indicating a structural shift in the company's growth and profitability drivers. Considering the accelerated growth of the company's overseas business, profit expansion driven by consumables sales, and effective cost control, it raised its target price from HKD 19.1 to HKD 30.9 and upgraded its rating from "Neutral" to "Overweight." During the period, the company's revenue grew by 77% year-on-year, and net losses narrowed by 59%; overseas sales increased by 189%, accounting for 58% of total revenue, reflecting the status of overseas business as its core engine. The report cited guidance from MicroPort Medbot's management, targeting approximately 85% revenue growth this year and further narrowing net losses, while strictly controlling capital expenditures between RMB 5 million and 10 million, with a goal of free cash outflow of less than RMB 200 million

According to the Zhitong Finance APP, JP Morgan released a research report stating that MicroPort Medbot-B (02252) showed a stronger-than-expected order trend in the first half of the year, indicating a structural shift in the company's growth and profitability drivers. Considering the accelerated growth of the company's overseas business, profit expansion driven by consumables sales, and effective cost control, it raised its target price from HKD 19.1 to HKD 30.9 and upgraded its rating from "Neutral" to "Overweight."

During the period, the company's revenue grew by 77% year-on-year, and net losses narrowed by 59%; overseas sales increased by 189%, accounting for 58% of total revenue, reflecting the status of overseas business as its core engine. The report cited guidance from MicroPort Medbot's management, targeting approximately 85% revenue growth this year and further narrowing net losses, while strictly controlling capital expenditures between RMB 5 million and 10 million, with a goal of free cash outflow of less than RMB 200 million

### Related Stocks

- [02252.HK - MircroPort Medbot-B](https://longbridge.com/en/quote/02252.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Outdoor camera, surveillance maker Tactacam explores sale, sources say | Tactacam, a maker of outdoor cameras and surveillance technology, is exploring a sale that could value the company at ov | [Link](https://longbridge.com/en/news/276168245.md) |
| Slovenia Issues 750 Million Euros in March 2036 Bond Syndicated Tap | Slovenia issued 750 million euros in a syndicated tap of its March 2036 bond, with demand exceeding 6.8 billion euros. T | [Link](https://longbridge.com/en/news/276059464.md) |
| 06:30 ETDress for Success® Worldwide lanza una campaña global y renueva su marca | Dress for Success Worldwide has launched a global campaign called "Success Starts Now," aimed at modernizing its brand a | [Link](https://longbridge.com/en/news/276117190.md) |
| 09:30 ETFrist Cressey Ventures Announces Oversubscribed $425M Fund IV to Reshape Care Delivery | Frist Cressey Ventures (FCV) has closed an oversubscribed $425 million Fund IV, increasing total assets under management | [Link](https://longbridge.com/en/news/276240520.md) |
| Best Linking Group expects full-year revenue to increase by 30%-40% | Best Linking Group expects full-year revenue to increase by 30%-40% | [Link](https://longbridge.com/en/news/275779661.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.